60 Degrees Pharma's Tafenoquine Phase 2 Babesiosis Study Clears Safety Hurdle, Recommended to Continue
SXTP sits 39% above its 52-week low of $1.22 on light trading volume (0.2× avg).
Summary
60 Degrees Pharmaceuticals received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) for its B-FREE Phase 2 study of tafenoquine for chronic babesiosis. The DSMB found no safety concerns and recommended the trial's continuation. This is a critical de-risking event for the micro-cap biotech, allowing its lead clinical program to advance. The news follows the early enrollment of the first patient in May and the company's intent to pursue a Priority Review Voucher for tafenoquine. This positive clinical progress is vital for the company, which recently disclosed a critical 4-month cash runway and proposed a highly dilutive reverse stock split and share increase.
At the time of this announcement, SXTP was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $1.22 to $10.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.